Skewing dendritic cell differentiation towards a tolerogenic state for recovery of tolerance in rheumatoid arthritis

Autoimmunity Reviews

Volumn 14, Issue 6, 2015, Pages 517-527

  Schinnerling, Katina ^a,b   Soto, Lilian ^a,b   García González, Paulina ^a,b   Catalán, Diego ^a,b   Aguillón, Juan C ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b Pontificia Universidad Católica de Chile   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BIOLOGICAL MARKER; TRANSCRIPTION FACTOR; AUTOANTIGEN;

AUTOIMMUNITY; CELL DIFFERENTIATION; CELL THERAPY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VITRO STUDY; PILOT STUDY; REVIEW; RHEUMATOID ARTHRITIS; THERAPY EFFECT; TOLEROGENIC DENDRITIC CELL; ANIMAL; CYTOLOGY; IMMUNOLOGY; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; T-LYMPHOCYTES;

EID: 84933670988     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.01.014     Document Type: Review

References (195)

1. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376(9746):1094-1108.
2. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73(3):492-509.
3. Quan L.D., Thiele G.M., Tian J., Wang D. The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat 2008, 18(7):723-738.
4. Romo-Tena J., Gomez-Martin D., Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 2013, 12(12):1171-1176.
5. Meier F.M., McInnes I.B. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol 2014, 28(4):605-624.
6. Chang C. Unmet needs in the treatment of autoimmunity: from aspirin to stem cells. Autoimmun Rev 2014, 13(4-5):331-346.
7. Van Brussel I., Lee W.P., Rombouts M., Nuyts A.H., Heylen M., De Winter B.Y., et al. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?. Autoimmun Rev 2014, 13(2):138-150.
8. Mackern-Oberti J.P., Llanos C., Vega F., Salazar-Onfray F., Riedel C.A., Bueno S.M., et al. Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases. Autoimmun Rev 2015, 14(2):127-139.
9. Pulendran B., Tang H., Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol 2010, 11(8):647-655.
10. Barber G.N. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol 2011, 23(1):10-20.
11. Rock K.L., Lai J.J., Kono H. Innate and adaptive immune responses to cell death. Immunol Rev 2011, 243(1):191-205.
12. Zelenay S., Reis e Sousa C. Adaptive immunity after cell death. Trends Immunol 2013, 34(7):329-335.
13. Ueno H., Klechevsky E., Morita R., Aspord C., Cao T., Matsui T., et al. Dendritic cell subsets in health and disease. Immunol Rev 2007, 219(1):118-142.
14. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005, 23:975-1028.
15. Platt C.D., Ma J.K., Chalouni C., Ebersold M., Bou-Reslan H., Carano R.A., et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci U S A 2010, 107(9):4287-4292.
16. Piqueras B., Connolly J., Freitas H., Palucka A.K., Banchereau J. Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood 2006, 107(7):2613-2618.
17. Han T.H., Jin P., Ren J., Slezak S., Marincola F.M., Stroncek D.F. Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother 2009, 32(4):399-407.
18. Delgado-Martín C., Escribano C., Pablos J.L., Riol-Blanco L., Rodríguez-Fernández J.L. Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells. J Biol Chem 2011, 286(43):37222-37236.
19. Dieu M.C., Vanbervliet B., Vicari A., Bridon J.M., Oldham E., Ait-Yahia S., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998, 188(2):373-386.
20. Chow A., Toomre D., Garrett W., Mellman I. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 2002, 418(6901):988-994.
21. Tanaka H., Demeure C.E., Rubio M., Delespesse G., Sarfati M. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. J Exp Med 2000, 192(3):405-412.
22. Satpathy A.T., Wu X., Albring J.C., Murphy K.M. Re(de)fining the dendritic cell lineage. Nat Immunol 2012, 13(12):1145-1154.
23. Jaehn P.S., Zaenker K.S., Schmitz J., Dzionek A. Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol 2008, 38(7):1822-1832.
24. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19(2):225-234.
25. MacDonald K.P., Munster D.J., Clark G.J., Dzionek A., Schmitz J., Hart D.N. Characterization of human blood dendritic cell subsets. Blood 2002, 100(13):4512-4520.
26. Lundberg K., Albrekt A.S., Nelissen I., Santegoets S., de Gruijl T.D., Gibbs S., et al. Transcriptional profiling of human dendritic cell populations and models-unique profiles of in vitro dendritic cells and implications on functionality and applicability. PLoS One 2013, 8(1):e52875.
27. Piccioli D., Tavarini S., Borgogni E., Steri V., Nuti S., Sammicheli C., et al. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 2007, 109(12):5371-5379.
28. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., et al. Human CD141+ (BDCA-3)+dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010, 207(6):1247-1260.
29. Campbell I.K., van Nieuwenhuijze A., Segura E., O'Donnell K., Coghill E., Hommel M., et al. Differentiation of inflammatory dendritic cells is mediated by NF-kappaB1-dependent GM-CSF production in CD4 T cells. J Immunol 2011, 186(9):5468-5477.
30. Segura E., Touzot M., Bohineust A., Cappuccio A., Chiocchia G., Hosmalin A., et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013, 38(2):336-348.
31. Zheng X., Vladau C., Shunner A., Min W.P. siRNA specific delivery system for targeting dendritic cells. Methods Mol Biol 2010, 623:173-188.
32. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179(4):1109-1118.
33. Leon B., Lopez-Bravo M., Ardavin C. Monocyte-derived dendritic cells. Semin Immunol 2005, 17(4):313-318.
34. Ohnmacht C., Pullner A., King S.B., Drexler I., Meier S., Brocker T., et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009, 206(3):549-559.
35. Brocker T., Riedinger M., Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 1997, 185(3):541-550.
36. McCaughtry T.M., Baldwin T.A., Wilken M.S., Hogquist K.A. Clonal deletion of thymocytes can occur in the cortex with no involvement of the medulla. J Exp Med 2008, 205(11):2575-2584.
37. Watanabe N., Wang Y.H., Lee H.K., Ito T., Wang Y.H., Cao W., et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005, 436(7054):1181-1185.
38. Singh R.P., Waldron R.T., Hahn B.H. Genes, tolerance and systemic autoimmunity. Autoimmun Rev 2012, 11(9):664-669.
39. Ito T., Yang M., Wang Y.H., Lande R., Gregorio J., Perng O.A., et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007, 204(1):105-115.
40. Gilliet M., Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002, 195(6):695-704.
41. de Heer H.J., Hammad H., Soullie T., Hijdra D., Vos N., Willart M.A., et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004, 200(1):89-98.
42. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
43. Vitali C., Mingozzi F., Broggi A., Barresi S., Zolezzi F., Bayry J., et al. Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood 2012, 120(6):1237-1245.
44. Sun C.M., Hall J.A., Blank R.B., Bouladoux N., Oukka M., Mora J.R., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. J Exp Med 2007, 204(8):1775-1785.
45. Khare A., Krishnamoorthy N., Oriss T.B., Fei M., Ray P., Ray A. Cutting edge: inhaled antigen upregulates retinaldehyde dehydrogenase in lung CD103+ but not plasmacytoid dendritic cells to induce Foxp3 de novo in CD4+ T cells and promote airway tolerance. J Immunol 2013, 191(1):25-29.
46. Guilliams M., Crozat K., Henri S., Tamoutounour S., Grenot P., Devilard E., et al. Skin-draining lymph nodes contain dermis-derived CD103(-) dendritic cells that constitutively produce retinoic acid and induce Foxp3(+) regulatory T cells. Blood 2010, 115(10):1958-1968.
47. Chu C.C., Ali N., Karagiannis P., Di Meglio P., Skowera A., Napolitano L., et al. Resident CD141 (BDCA3)+dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med 2012, 209(5):935-945.
48. Azukizawa H., Dohler A., Kanazawa N., Nayak A., Lipp M., Malissen B., et al. Steady state migratory RelB+ langerin+dermal dendritic cells mediate peripheral induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells. Eur J Immunol 2011, 41(5):1420-1434.
49. van der Aar A.M., Picavet D.I., Muller F.J., de Boer L., van Capel T.M., Zaat S.A., et al. Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol 2013, 133(5):1240-1249.
50. Bamboat Z.M., Stableford J.A., Plitas G., Burt B.M., Nguyen H.M., Welles A.P., et al. Human liver dendritic cells promote T cell hyporesponsiveness. J Immunol 2009, 182(4):1901-1911.
51. Gregori S., Tomasoni D., Pacciani V., Scirpoli M., Battaglia M., Magnani C.F., et al. Differentiation of type 1T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010, 116(6):935-944.
52. Joffre O.P., Sancho D., Zelenay S., Keller A.M., Reis e Sousa C. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur J Immunol 2010, 40(5):1255-1265.
53. Thomas R., Davis L.S., Lipsky P.E. Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J Immunol 1994, 152(5):2613-2623.
54. Thomas R., Quinn C. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J Immunol 1996, 156(8):3074-3086.
55. Santiago-Schwarz F., Anand P., Liu S., Carsons S.E. Dendritic cells (DCs) in rheumatoid arthritis (RA): progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate Th1 inflammatory-type responses. J Immunol 2001, 167(3):1758-1768.
56. Tsark E.C., Wang W., Teng Y.C., Arkfeld D., Dodge G.R., Kovats S. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 2002, 169(11):6625-6633.
57. Page G., Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 2005, 52(8):2307-2312.
58. Pettit A.R., MacDonald K.P., O'Sullivan B., Thomas R. Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum 2000, 43(4):791-800.
59. Jongbloed S.L., Lebre M.C., Fraser A.R., Gracie J.A., Sturrock R.D., Tak P.P., et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther 2006, 8(1):R15.
60. Moret F.M., Hack C.E., van der Wurff-Jacobs K.M., de Jager W., Radstake T.R., Lafeber F.P., et al. Intra-articular CD1c-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Th1, Th17 and Th2 cell activity. Arthritis Res Ther 2013, 15(5):R155.
61. Lebre M.C., Jongbloed S.L., Tas S.W., Smeets T.J., McInnes I.B., Tak P.P. Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine profiles. Am J Pathol 2008, 172(4):940-950.
62. Bonnefoy F., Couturier M., Clauzon A., Remy-Martin J.P., Gaugler B., Tiberghien P., et al. TGF-beta-exposed plasmacytoid dendritic cells participate in Th17 commitment. J Immunol 2011, 186(11):6157-6164.
63. Kavousanaki M., Makrigiannakis A., Boumpas D., Verginis P. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum 2010, 62(1):53-63.
64. Jongbloed S.L., Benson R.A., Nickdel M.B., Garside P., McInnes I.B., Brewer J.M. Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. J Immunol 2009, 182(2):963-968.
65. Segura E., Amigorena S. Identification of human inflammatory dendritic cells. Oncoimmunology 2013, 2(5):e23851.
66. Lakey R.L., Morgan T.G., Rowan A.D., Isaacs J.D., Cawston T.E., Hilkens C.M. A novel paradigm for dendritic cells as effectors of cartilage destruction. Rheumatology (Oxford) 2009, 48(5):502-507.
67. Leung B.P., Conacher M., Hunter D., McInnes I.B., Liew F.Y., Brewer J.M. A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J Immunol 2002, 169(12):7071-7077.
68. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50(5):1400-1411.
69. Hilkens C.M., Isaacs J.D. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?. Clin Exp Immunol 2013, 172(2):148-157.
70. Thomas R. Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. Arthritis Res Ther 2013, 15(1):204.
71. Reynolds G., Cooles F.A., Isaacs J.D., Hilkens C.M. Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother 2014, 10(4):822-837.
72. Thomas R. Dendritic cells as targets or therapeutics in rheumatic autoimmune disease. Curr Opin Rheumatol 2014, 26(2):211-218.
73. Coleman M.A., Steptoe R.J. Induction of antigen-specific tolerance through hematopoietic stem cell-mediated gene therapy: the future for therapy of autoimmune disease?. Autoimmun Rev 2012, 12(2):195-203.
74. Steinbrink K., Wolfl M., Jonuleit H., Knop J., Enk A.H. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997, 159(10):4772-4780.
75. Fogel-Petrovic M., Long J.A., Misso N.L., Foster P.S., Bhoola K.D., Thompson P.J. Physiological concentrations of transforming growth factor beta1 selectively inhibit human dendritic cell function. Int Immunopharmacol 2007, 7(14):1924-1933.
76. Brandt K., Bulfone-Paus S., Foster D.C., Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003, 102(12):4090-4098.
77. Rutella S., Danese S., Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108(5):1435-1440.
78. Hegde S., Pahne J., Smola-Hess S. Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression. FASEB J 2004, 18(12):1439-1441.
79. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002, 195(1):15-21.
80. Torres-Aguilar H., Aguilar-Ruiz S.R., González-Pérez G., Munguía R., Bajaña S., Meraz-Ríos M.A., et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T Cells. J Immunol 2010, 184(4):1765-1775.
81. Salazar L., Aravena O., Abello P., Escobar A., Contreras-Levicoy J., Rojas-Colonelli N., et al. Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. Ann Rheum Dis 2008, 67(9):1235-1241.
82. Zimmer A., Bouley J., Le Mignon M., Pliquet E., Horiot S., Turfkruyer M., et al. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. J Allergy Clin Immunol 2012, 129(4):1020-1030.
83. Xia C.Q., Peng R., Beato F., Clare-Salzler M.J. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Immunol 2005, 62(1):45-54.
84. Hackstein H., Taner T., Zahorchak A.F., Morelli A.E., Logar A.J., Gessner A., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101(11):4457-4463.
85. Buckland M., Jago C., Fazekesova H., George A., Lechler R., Lombardi G. Aspirin modified dendritic cells are potent inducers of allo-specific regulatory T-cells. Int Immunopharmacol 2006, 6(13-14):1895-1901.
86. Lee J.I., Ganster R.W., Geller D.A., Burckart G.J., Thomson A.W., Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 1999, 68(9):1255-1263.
87. Lagaraine C., Lemoine R., Baron C., Nivet H., Velge-Roussel F., Lebranchu Y. Induction of human CD4+ regulatory T cells by mycophenolic acid-treated dendritic cells. J Leukoc Biol 2008, 84(4):1057-1064.
88. Kubo S., Yamaoka K., Kondo M., Yamagata K., Zhao J., Iwata S., et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 2014, 73(12):2192-2198.
89. Svajger U., Obermajer N., Jeras M. Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation. Immunology 2010, 129(4):525-535.
90. Rogers N.M., Kireta S., Coates P.T. Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo. Clin Exp Immunol 2010, 162(3):460-473.
91. Geisel J., Bruck J., Glocova I., Dengler K., Sinnberg T., Rothfuss O., et al. Sulforaphane protects from T cell-mediated autoimmune disease by inhibition of IL-23 and IL-12 in dendritic cells. J Immunol 2014, 192(8):3530-3539.
92. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164(5):2405-2411.
93. Harry R.A., Anderson A.E., Isaacs J.D., Hilkens C.M. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010, 69(11):2042-2050.
94. Chorny A., Gonzalez-Rey E., Fernandez-Martin A., Pozo D., Ganea D., Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci U S A 2005, 102(38):13562-13567.
95. Matsumoto T., Hasegawa H., Onishi S., Ishizaki J., Suemori K., Yasukawa M. Protein kinase C inhibitor generates stable human tolerogenic dendritic cells. J Immunol 2013, 191(5):2247-2257.
96. Martin E., Capini C., Duggan E., Lutzky V.P., Stumbles P., Pettit A.R., et al. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum 2007, 56(7):2255-2266.
97. Iruretagoyena M.I., Sepulveda S.E., Lezana J.P., Hermoso M., Bronfman M., Gutierrez M.A., et al. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2006, 318(1):59-67.
98. Ko H.J., Cho M.L., Lee S.Y., Oh H.J., Heo Y.J., Moon Y.M., et al. CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell population. J Autoimmun 2010, 34(2):111-120.
99. Henry E., Desmet C.J., Garzé V., Fiévez L., Bedoret D., Heirman C., et al. Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J Immunol 2008, 181(10):7230-7242.
100. Kim S.H., Kim S., Evans C.H., Ghivizzani S.C., Oligino T., Robbins P.D. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001, 166(5):3499-3505.
101. Zheng X., Suzuki M., Ichim T.E., Zhang X., Sun H., Zhu F., et al. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010, 184(11):6457-6464.
102. Unger W.W., Laban S., Kleijwegt F.S., van der Slik A.R., Roep B.O. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009, 39(11):3147-3159.
103. Garcia-Gonzalez P., Morales R., Hoyos L., Maggi J., Campos J., Pesce B., et al. A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. J Transl Med 2013, 11:128.
104. Naranjo-Gomez M., Raich-Regue D., Onate C., Grau-Lopez L., Ramo-Tello C., Pujol-Borrell R., et al. Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med 2011, 9(1):89.
105. Boks M.A., Kager-Groenland J.R., Haasjes M.S.P., Zwaginga J.J., van Ham S.M., ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction - a comparative study of human clinical-applicable DC. Clin Immunol 2012, 142(3):332-342.
106. Anderson A.E., Swan D.J., Sayers B.L., Harry R.A., Patterson A.M., von Delwig A., et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009, 85(2):243-250.
107. Holmdahl R., Andersson M.E., Goldschmidt T.J., Jansson L., Karlsson M., Malmstrom V., et al. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS 1989, 97(7):575-584.
108. van Duivenvoorde L.M., Han W.G.H., Bakker A.M., Louis-Plence P., Charbonnier L.-M., Apparailly F., et al. Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms. J Immunol 2007, 179(3):1506-1515.
109. Orange D.E., Blachere N.E., Fak J., Parveen S., Frank M.O., Herre M., et al. Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo. Elife 2013, 2:e00105.
110. Stoop J.N., Harry R.A., von Delwig A., Isaacs J.D., Robinson J.H., Hilkens C.M.U. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum 2010, 62(12):3656-3665.
111. Garate D., Rojas-Colonelli N., Pena C., Salazar L., Abello P., Pesce B., et al. Blocking of p38 and transforming growth factor beta receptor pathways impairs the ability of tolerogenic dendritic cells to suppress murine arthritis. Arthritis Rheum 2013, 65(1):120-129.
112. Yang J., Yang Y., Ren Y., Xie R., Zou H., Fan H. A mouse model of adoptive immunotherapeutic targeting of autoimmune arthritis using allo-tolerogenic dendritic cells. PLoS One 2013, 8(10):e77729.
113. Ren Y., Yang Y., Yang J., Xie R., Fan H. Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice. Int Immunopharmacol 2014, 21(1):247-254.
114. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172(5):2731-2738.
115. Hensvold A.H., Magnusson P.K., Joshua V., Hansson M., Israelsson L., Ferreira R., et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis 2015, 74(2):375-380.
116. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001, 193(2):233-238.
117. Giannoukakis N., Phillips B., Finegold D., Harnaha J., Trucco M. Phase I (Safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011, 34(9):2026-2032.
118. Di Caro V., Phillips B., Engman C., Harnaha J., Trucco M., Giannoukakis N. Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B lymphocytes. Clin Exp Immunol 2013, 174(2):302-317.
119. Di Caro V., Phillips B., Engman C., Harnaha J., Trucco M., Giannoukakis N. Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice. PLoS One 2014, 9(1):e83575.
120. Thomas R., Street S. Safety and preliminary evidence of efficacy in a phase I clinical trial of autologous tolerising dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70(Suppl. 3):169.
121. Ferreira G.B., Kleijwegt F.S., Waelkens E., Lage K., Nikolic T., Hansen D.A., et al. Differential protein pathways in 1,25-dihydroxyvitamin d(3) and dexamethasone modulated tolerogenic human dendritic cells. J Proteome Res 2012, 11(2):941-971.
122. Gomez-Martin D., Diaz-Zamudio M., Galindo-Campos M., Alcocer-Varela J. Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity. Autoimmun Rev 2010, 9(6):454-458.
123. Hammer G.E., Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol 2013, 31:743-791.
124. Tong X., Yin L., Washington R., Rosenberg D.W., Giardina C. The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem 2004, 265(1-2):171-183.
125. Cao S., Zhang X., Edwards J.P., Mosser D.M. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 2006, 281(36):26041-26050.
126. Dissanayake D., Hall H., Berg-Brown N., Elford A.R., Hamilton S.R., Murakami K., et al. Nuclear factor-kappaB1 controls the functional maturation of dendritic cells and prevents the activation of autoreactive T cells. Nat Med 2011, 17(12):1663-1667.
127. Larghi P., Porta C., Riboldi E., Totaro M.G., Carraro L., Orabona C., et al. The p50 subunit of NF-kappaB orchestrates dendritic cell lifespan and activation of adaptive immunity. PLoS One 2012, 7(9):e45279.
128. Bhattacharyya S., Zhao Y., Kay T.W., Muglia L.J. Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate toll-like receptor-induced STAT1 activation. Proc Natl Acad Sci U S A 2011, 108(23):9554-9559.
129. Hanada T., Yoshida H., Kato S., Tanaka K., Masutani K., Tsukada J., et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003, 19(3):437-450.
130. Hanada T., Tanaka K., Matsumura Y., Yamauchi M., Nishinakamura H., Aburatani H., et al. Induction of hyper Th1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene. J Immunol 2005, 174(7):4325-4332.
131. Park S.J., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S., et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004, 173(6):3844-3854.
132. Melillo J.A., Song L., Bhagat G., Blazquez A.B., Plumlee C.R., Lee C., et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol 2010, 184(5):2638-2645.
133. Kowalczyk A., D'Souza C.A., Zhang L. Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3. Eur J Immunol 2014, 44(4):1143-1155.
134. Matsumura Y., Kobayashi T., Ichiyama K., Yoshida R., Hashimoto M., Takimoto T., et al. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J Immunol 2007, 179(4):2170-2179.
135. Li Y., Chu N., Rostami A., Zhang G.X. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol 2006, 177(3):1679-1688.
136. Gosset P., Charbonnier A.S., Delerive P., Fontaine J., Staels B., Pestel J., et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 2001, 31(10):2857-2865.
137. Nencioni A., Grunebach F., Zobywlaski A., Denzlinger C., Brugger W., Brossart P. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol 2002, 169(3):1228-1235.
138. Housley W.J., O'Conor C.A., Nichols F., Puddington L., Lingenheld E.G., Zhu L., et al. PPARgamma regulates retinoic acid-mediated DC induction of Tregs. J Leukoc Biol 2009, 86(2):293-301.
139. Cohen N., Mouly E., Hamdi H., Maillot M.C., Pallardy M., Godot V., et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 2006, 107(5):2037-2044.
140. Ayroldi E., Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009, 23(11):3649-3658.
141. Hamdi H., Godot V., Maillot M.C., Prejean M.V., Cohen N., Krzysiek R., et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood 2007, 110(1):211-219.
142. Benkhoucha M., Molnarfi N., Dunand-Sauthier I., Merkler D., Schneiter G., Bruscoli S., et al. Hepatocyte growth factor limits autoimmune neuroinflammation via glucocorticoid-induced leucine zipper expression in dendritic cells. J Immunol 2014, 193(6):2743-2752.
143. Nguyen N.T., Kimura A., Nakahama T., Chinen I., Masuda K., Nohara K., et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 2010, 107(46):19961-19966.
144. Chan Y.H., Chiang M.F., Tsai Y.C., Su S.T., Chen M.H., Hou M.S., et al. Absence of the transcriptional repressor Blimp-1 in hematopoietic lineages reveals its role in dendritic cell homeostatic development and function. J Immunol 2009, 183(11):7039-7046.
145. Kim S.J., Zou Y.R., Goldstein J., Reizis B., Diamond B. Tolerogenic function of Blimp-1 in dendritic cells. J Exp Med 2011, 208(11):2193-2199.
146. Cella M., Dohring C., Samaridis J., Dessing M., Brockhaus M., Lanzavecchia A., et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 1997, 185(10):1743-1751.
147. Colonna M., Samaridis J., Cella M., Angman L., Allen R.L., O'Callaghan C.A., et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998, 160(7):3096-3100.
148. Brenk M., Scheler M., Koch S., Neumann J., Takikawa O., Hacker G., et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. J Immunol 2009, 183(1):145-154.
149. Ge G., Tian P., Liu H., Zheng J., Fan X., Ding C., et al. Induction of CD4+ CD25+ Foxp3+ T regulatory cells by dendritic cells derived from ILT3 lentivirus-transduced human CD34+ cells. Transpl Immunol 2012, 26(1):19-26.
150. Gianchecchi E., Delfino D.V., Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev 2013, 12(11):1091-1100.
151. Pedersen A.W., Holmstrom K., Jensen S.S., Fuchs D., Rasmussen S., Kvistborg P., et al. Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol 2009, 157(1):48-59.
152. Manicassamy S., Ravindran R., Deng J., Oluoch H., Denning T.L., Kasturi S.P., et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med 2009, 15(4):401-409.
153. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002, 196(12):1627-1638.
154. Ring S., Maas M., Nettelbeck D.M., Enk A.H., Mahnke K. Targeting of autoantigens to DEC205(+) dendritic cells in vivo suppresses experimental allergic encephalomyelitis in mice. J Immunol 2013, 191(6):2938-2947.
155. Fujikado N., Saijo S., Yonezawa T., Shimamori K., Ishii A., Sugai S., et al. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat Med 2008, 14(2):176-180.
156. Zhou Y., Kawasaki H., Hsu S.C., Lee R.T., Yao X., Plunkett B., et al. Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1. Nat Med 2010, 16(10):1128-1133.
157. Samsom J.N., van Berkel L.A., van Helvoort J.M., Unger W.W., Jansen W., Thepen T., et al. Fc gamma RIIB regulates nasal and oral tolerance: a role for dendritic cells. J Immunol 2005, 174(9):5279-5287.
158. Desai D.D., Harbers S.O., Flores M., Colonna L., Downie M.P., Bergtold A., et al. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 2007, 178(10):6217-6226.
159. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005, 115(10):2914-2923.
160. Rothlin C.V., Ghosh S., Zuniga E.I., Oldstone M.B., Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007, 131(6):1124-1136.
161. Lu Q., Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001, 293(5528):306-311.
162. Hammer G.E., Turer E.E., Taylor K.E., Fang C.J., Advincula R., Oshima S., et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 2011, 12(12):1184-1193.
163. Kool M., van Loo G., Waelput W., De Prijck S., Muskens F., Sze M., et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011, 35(1):82-96.
164. Musone S.L., Taylor K.E., Nititham J., Chu C., Poon A., Liao W., et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011, 12(3):176-182.
165. Chauveau C., Remy S., Royer P.J., Hill M., Tanguy-Royer S., Hubert F.X., et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005, 106(5):1694-1702.
166. Blancou P., Tardif V., Simon T., Remy S., Carreno L., Kalergis A., et al. Immunoregulatory properties of heme oxygenase-1. Methods Mol Biol 2011, 677:247-268.
167. Remy S., Blancou P., Tesson L., Tardif V., Brion R., Royer P.J., et al. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. J Immunol 2009, 182(4):1877-1884.
168. Simon T., Pogu S., Tardif V., Rigaud K., Remy S., Piaggio E., et al. Carbon monoxide-treated dendritic cells decrease beta1-integrin induction on CD8(+) T cells and protect from type 1 diabetes. Eur J Immunol 2013, 43(1):209-218.
169. Puig-Kroger A., Relloso M., Fernandez-Capetillo O., Zubiaga A., Silva A., Bernabeu C., et al. Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 2001, 98(7):2175-2182.
170. Arce F., Breckpot K., Stephenson H., Karwacz K., Ehrenstein M.R., Collins M., et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum 2011, 63(1):84-95.
171. Ramachandran I.R., Song W., Lapteva N., Seethammagari M., Slawin K.M., Spencer D.M., et al. The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol 2011, 186(7):3934-3945.
172. Kaneko T., Saito Y., Kotani T., Okazawa H., Iwamura H., Sato-Hashimoto M., et al. Dendritic cell-specific ablation of the protein tyrosine phosphatase Shp1 promotes Th1 cell differentiation and induces autoimmunity. J Immunol 2012, 188(11):5397-5407.
173. Lamagna C., Scapini P., van Ziffle J.A., DeFranco A.L., Lowell C.A. Hyperactivated MyD88 signaling in dendritic cells, through specific deletion of Lyn kinase, causes severe autoimmunity and inflammation. Proc Natl Acad Sci U S A 2013, 110(35):E3311-E3320.
174. Mascanfroni I.D., Yeste A., Vieira S.M., Burns E.J., Patel B., Sloma I., et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 2013, 14(10):1054-1063.
175. Manicassamy S., Reizis B., Ravindran R., Nakaya H., Salazar-Gonzalez R.M., Wang Y.C., et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010, 329(5993):849-853.
176. Oderup C., LaJevic M., Butcher E.C. Canonical and noncanonical Wnt proteins program dendritic cell responses for tolerance. J Immunol 2013, 190(12):6126-6134.
177. Valencia J., Hernandez-Lopez C., Martinez V.G., Hidalgo L., Zapata A.G., Vicente A., et al. Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. J Immunol 2011, 187(8):4129-4139.
178. Jinushi M., Nakazaki Y., Dougan M., Carrasco D.R., Mihm M., Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest 2007, 117(7):1902-1913.
179. Baghdadi M., Chiba S., Yamashina T., Yoshiyama H., Jinushi M. MFG-E8 regulates the immunogenic potential of dendritic cells primed with necrotic cell-mediated inflammatory signals. PLoS One 2012, 7(6):e39607.
180. Castellano G., Woltman A.M., Nauta A.J., Roos A., Trouw L.A., Seelen M.A., et al. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 2004, 103(10):3813-3820.
181. Teh B.K., Yeo J.G., Chern L.M., Lu J. C1q regulation of dendritic cell development from monocytes with distinct cytokine production and T cell stimulation. Mol Immunol 2011, 48(9-10):1128-1138.
182. Hosszu K.K., Valentino A., Vinayagasundaram U., Vinayagasundaram R., Joyce M.G., Ji Y., et al. DC-SIGN, C1q, and gC1qR form a trimolecular receptor complex on the surface of monocyte-derived immature dendritic cells. Blood 2012, 120(6):1228-1236.
183. Driessler F., Venstrom K., Sabat R., Asadullah K., Schottelius A.J. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 2004, 135(1):64-73.
184. Nefedova Y., Cheng P., Gilkes D., Blaskovich M., Beg A.A., Sebti S.M., et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005, 175(7):4338-4346.
185. Vogel C.F., Wu D., Goth S.R., Baek J., Lollies A., Domhardt R., et al. Aryl hydrocarbon receptor signaling regulates NF-kappaB RelB activation during dendritic-cell differentiation. Immunol Cell Biol 2013, 91(9):568-575.
186. Gerbal-Chaloin S., Iankova I., Maurel P., Daujat-Chavanieu M. Nuclear receptors in the cross-talk of drug metabolism and inflammation. Drug Metab Rev 2013, 45(1):122-144.
187. Scapini P., Pereira S., Zhang H., Lowell C.A. Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunol Rev 2009, 228(1):23-40.
188. Chamorro S., Garcia-Vallejo J.J., Unger W.W., Fernandes R.J., Bruijns S.C., Laban S., et al. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J Immunol 2009, 183(5):2984-2994.
189. Shrimpton R.E., Butler M., Morel A.S., Eren E., Hue S.S., Ritter M.A. CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self. Mol Immunol 2009, 46(6):1229-1239.
190. Klechevsky E., Flamar A.L., Cao Y., Blanck J.P., Liu M., O'Bar A., et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010, 116(10):1685-1697.
191. Meyer-Wentrup F., Cambi A., Joosten B., Looman M.W., de Vries I.J., Figdor C.G., et al. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J Leukoc Biol 2009, 85(3):518-525.
192. Gringhuis S.I., den Dunnen J., Litjens M., van Het Hof B., van Kooyk Y., Geijtenbeek T.B. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 2007, 26(5):605-616.
193. Zhou M., Peng J.R., Zhang H.G., Wang H.X., Zhong Z.H., Pan X.Y., et al. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry. Immunol Lett 2005, 99(1):113-121.
194. Caparros E., Munoz P., Sierra-Filardi E., Serrano-Gomez D., Puig-Kroger A., Rodriguez-Fernandez J.L., et al. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood 2006, 107(10):3950-3958.
195. Bergenfelz C., Janols H., Wullt M., Jirstrom K., Bredberg A., Leandersson K. Wnt5a inhibits human monocyte-derived myeloid dendritic cell generation. Scand J Immunol 2013, 78(2):194-204.